NWBO OTC
Northwest Biotherapeutics, Inc.
1W: -6.2%
1M: -11.4%
3M: -20.1%
YTD: -41.1%
1Y: -39.7%
3Y: -81.9%
5Y: -89.7%
$0.15
-0.00 (-1.51%)
Weekly Expected Move ±5.5%
$0
$0
$0
$0
$0
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
Dark Pool
Short Interest
Supply Chain
Income Trends
Revenue
$1M
-28.5% ▼
5Y CAGR: -10.5%
Gross Profit
$1M
+105.4% ▲
Operating Income
-$67M
-19.8% ▼
Net Income
-$84M
-33.8% ▼
EPS (Diluted)
$-0.07
-14.3% ▼
EBITDA
-$74M
-33.1% ▼
Profit Margins
Year-over-Year Growth
View Full Income Statement
| Line Item | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 |
|---|---|---|---|---|---|
| Revenue | $1M | $1M | $2M | $2M | $1M |
| YoY Growth | -46.4% | -22.2% | +67.5% | +14.8% | -28.5% |
| Cost of Revenue | $34M | $20M | $2M | $28M | $0 |
| Gross Profit | -$32M | -$19M | $135K | -$26M | $1M |
| Gross Margin | -2505.5% | -1920.7% | 8.0% | -1335.3% | 100.0% |
| R&D Expenses | $34M | $20M | $36M | $28M | $35M |
| SG&A Expenses | $54M | $33M | $33M | $30M | $33M |
| Operating Expenses | $54M | $54M | $69M | $57M | $68M |
| Operating Income | -$87M | -$53M | -$67M | -$56M | -$67M |
| Operating Margin | -6708.4% | -5244.0% | -3991.7% | -2873.1% | -4812.4% |
| Interest Expense | $9M | $5M | $6M | $5M | $8M |
| Income Before Tax | -$530M | $179M | -$105M | -$63M | -$84M |
| Tax Expense | $0 | $0 | $0 | $0 | $0 |
| Net Income | -$530M | $179M | -$105M | -$63M | -$84M |
| Net Margin | -41039.6% | 17823.5% | -6240.8% | -3240.1% | -6062.1% |
| EPS (Diluted) | $-0.73 | $-0.06 | $-0.10 | $-0.06 | $-0.07 |
| EBITDA | -$521M | $185M | -$97M | -$55M | -$74M |
| Shares Outstanding | 725M | 1.01B | 1.02B | 1.12B | 1.24B |